CORVUS PHARMACEUTICALS INC (CRVS) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:CRVS • US2210151005

20.46 USD
+1.4 (+7.35%)
At close: Feb 6, 2026
20.2 USD
-0.26 (-1.27%)
After Hours: 2/6/2026, 8:26:36 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

CRVS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. While CRVS has a great health rating, there are worries on its profitability. CRVS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CRVS had negative earnings in the past year.
  • CRVS had a negative operating cash flow in the past year.
  • CRVS had negative earnings in each of the past 5 years.
  • CRVS had a negative operating cash flow in each of the past 5 years.
CRVS Yearly Net Income VS EBIT VS OCF VS FCFCRVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • CRVS's Return On Assets of -18.73% is fine compared to the rest of the industry. CRVS outperforms 77.33% of its industry peers.
  • CRVS's Return On Equity of -21.01% is amongst the best of the industry. CRVS outperforms 82.67% of its industry peers.
Industry RankSector Rank
ROA -18.73%
ROE -21.01%
ROIC N/A
ROA(3y)-70.1%
ROA(5y)-51.36%
ROE(3y)-111.59%
ROE(5y)-77.52%
ROIC(3y)N/A
ROIC(5y)N/A
CRVS Yearly ROA, ROE, ROICCRVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

  • CRVS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRVS Yearly Profit, Operating, Gross MarginsCRVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for CRVS has been increased compared to 1 year ago.
  • The number of shares outstanding for CRVS has been increased compared to 5 years ago.
  • CRVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRVS Yearly Shares OutstandingCRVS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CRVS Yearly Total Debt VS Total AssetsCRVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

  • CRVS has an Altman-Z score of 97.63. This indicates that CRVS is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of CRVS (97.63) is better than 98.86% of its industry peers.
  • There is no outstanding debt for CRVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 97.63
ROIC/WACCN/A
WACCN/A
CRVS Yearly LT Debt VS Equity VS FCFCRVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 8.29 indicates that CRVS has no problem at all paying its short term obligations.
  • CRVS's Current ratio of 8.29 is fine compared to the rest of the industry. CRVS outperforms 75.81% of its industry peers.
  • A Quick Ratio of 8.29 indicates that CRVS has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 8.29, CRVS is in the better half of the industry, outperforming 75.81% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.29
Quick Ratio 8.29
CRVS Yearly Current Assets VS Current LiabilitesCRVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • CRVS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.89%, which is quite impressive.
EPS 1Y (TTM)78.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, CRVS will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.11% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y71.94%
EPS Next 2Y16.12%
EPS Next 3Y9.9%
EPS Next 5Y17.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRVS Yearly Revenue VS EstimatesCRVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
CRVS Yearly EPS VS EstimatesCRVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • CRVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRVS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRVS Price Earnings VS Forward Price EarningsCRVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRVS Per share dataCRVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.12%
EPS Next 3Y9.9%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CRVS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CORVUS PHARMACEUTICALS INC

NASDAQ:CRVS (2/6/2026, 8:26:36 PM)

After market: 20.2 -0.26 (-1.27%)

20.46

+1.4 (+7.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04
Earnings (Next)03-05
Inst Owners39.01%
Inst Owner Change0.26%
Ins Owners3.95%
Ins Owner Change6.84%
Market Cap1.53B
Revenue(TTM)N/A
Net Income(TTM)-15.07M
Analysts86.15
Price Target35.7 (74.49%)
Short Float %19.76%
Short Ratio2.89
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.85%
Min EPS beat(2)11.83%
Max EPS beat(2)29.87%
EPS beat(4)3
Avg EPS beat(4)66.86%
Min EPS beat(4)-47.55%
Max EPS beat(4)273.3%
EPS beat(8)5
Avg EPS beat(8)-10.56%
EPS beat(12)8
Avg EPS beat(12)-6.23%
EPS beat(16)9
Avg EPS beat(16)-12.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)128.26%
PT rev (3m)133.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.46%
EPS NY rev (1m)5.4%
EPS NY rev (3m)3.72%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 21.29
P/tB 21.29
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0
BVpS0.96
TBVpS0.96
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -18.73%
ROE -21.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.1%
ROA(5y)-51.36%
ROE(3y)-111.59%
ROE(5y)-77.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.29
Quick Ratio 8.29
Altman-Z 97.63
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80%
EPS Next Y71.94%
EPS Next 2Y16.12%
EPS Next 3Y9.9%
EPS Next 5Y17.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-54.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-42.79%
EBIT Next 3Y-33.51%
EBIT Next 5Y43.26%
FCF growth 1Y-22.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.9%
OCF growth 3YN/A
OCF growth 5YN/A

CORVUS PHARMACEUTICALS INC / CRVS FAQ

What is the fundamental rating for CRVS stock?

ChartMill assigns a fundamental rating of 3 / 10 to CRVS.


Can you provide the valuation status for CORVUS PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to CORVUS PHARMACEUTICALS INC (CRVS). This can be considered as Overvalued.


Can you provide the profitability details for CORVUS PHARMACEUTICALS INC?

CORVUS PHARMACEUTICALS INC (CRVS) has a profitability rating of 1 / 10.


What is the earnings growth outlook for CORVUS PHARMACEUTICALS INC?

The Earnings per Share (EPS) of CORVUS PHARMACEUTICALS INC (CRVS) is expected to grow by 71.94% in the next year.